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Abstract
Background: There is a need to improve prediction of response to chemotherapy in breast cancer in order to improve
clinical management and this may be achieved by harnessing computational metrics of tissue pathology. We investigated
the association between quantitative image metrics derived from computational analysis of digital pathology slides and
response to chemotherapy in women with breast cancer who received neoadjuvant chemotherapy.
Methods: We digitised tissue sections of both diagnostic and surgical samples of breast tumours from 768 patients
enrolled in the Neo-tAnGo randomized controlled trial. We subjected digital images to systematic analysis optimised for
detection of single cells. Machine-learning methods were used to classify cells as cancer, stromal or lymphocyte and we
computed estimates of absolute numbers, relative fractions and cell densities using these data. Pathological complete
response (pCR), a histological indicator of chemotherapy response, was the primary endpoint. Fifteen image metrics were
tested for their association with pCR using univariate and multivariate logistic regression.
Results: Median lymphocyte density proved most strongly associated with pCR on univariate analysis (OR 4.46,
95 % CI 2.34-8.50, p < 0.0001; observations = 614) and on multivariate analysis (OR 2.42, 95 % CI 1.08-5.40, p = 0.03;
observations = 406) after adjustment for clinical factors. Further exploratory analyses revealed that in approximately
one quarter of cases there was an increase in lymphocyte density in the tumour removed at surgery compared to
diagnostic biopsies. A reduction in lymphocyte density at surgery was strongly associated with pCR (OR 0.28, 95 %
CI 0.17-0.47, p < 0.0001; observations = 553).
Conclusions: A data-driven analysis of computational pathology reveals lymphocyte density as an independent
predictor of pCR. Paradoxically an increase in lymphocyte density, following exposure to chemotherapy, is
associated with a lack of pCR. Computational pathology can provide objective, quantitative and reproducible
tissue metrics and represents a viable means of outcome prediction in breast cancer.
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Background
Women with high-risk early breast cancer are increasingly
being offered chemotherapy before definitive surgery
because neoadjuvant chemotherapy can enable breast-
conserving surgery [1]. Complete eradication of tumour
cells in the surgically removed tumour bed or pathological
complete response (pCR) is associated with improved sur-
vival [2, 3]. The likelihood of pCR is profoundly affected by
the oestrogen receptor (ER) and human epidermal growth
factor receptor 2 (HER2) status of the primary tumour
[2, 4]. In spite of these differences, improved prediction
of the probability of pCR is needed because alternative
regimens of chemotherapy or enrolment in clinical trials
might be offered to patients deemed unlikely to experience
pCR at baseline.
Novel pathological and genomic predictors of pCR have
been described. Hatzis et al. used gene-expression micro-
arrays to generate a gene set encompassing modules for
response to endocrine therapy and cytotoxic chemother-
apy, which identified patients likely to undergo pCR and
to have longer survival [5]. The proportion of tumour in-
filtrating lymphocytes has also been shown to predict pCR
in several studies of neoadjuvant chemotherapy [6–12].
Automated quantitative estimates of tumour morphology
using digital images of tissue sections have been shown to
be associated with prognosis [13, 14]. Therefore, compar-
able computational analysis of histological sections might
provide a similar method for prediction of pCR.
We hypothesized that systematic quantitative analysis
of tumour morphology at diagnosis would objectively
identify tissue characteristics associated with pCR. We
undertook a digital pathology study using a newly devel-
oped image processing method for single cell detection
and material from the Neo-tAnGo randomized controlled
trial [15], both from diagnosis and at surgery, in order to
objectively identify tissue features associated with pCR
and to investigate changes in quantitative morphological
metrics between pre-treatment and post-treatment sam-
ples and their relationship to pCR.
Methods
Patients and clinical samples
Neo-tAnGo was a phase III, randomized trial with two-
by-two factorial design addressing both the role of
gemcitabine in a sequential neoadjuvant chemotherapy
regimen of epirubicin/cyclophosphamide and paclitaxel,
and the role of sequencing of these treatment components
[15]. The trial recruited women with high-risk early breast
cancer between 2005 and 2007 across 57 centres in the
UK. Women with HER2-positive disease did not receive
neo-adjuvant trastuzumab although most did receive adju-
vant trastuzumab depending on local protocols. A total of
812 patients were included in the primary endpoint ana-
lysis [15]. Pathological complete response, the primary
endpoint, was defined as the complete absence of tumour
cells in resected breast tissue and axillary lymph nodes.
Whether pCR had occurred was determined by independ-
ent analysis of histopathology reports by two investigators
(EP and HME) as previously described [16]. The trial
found no effect of the addition of gemcitabine on the pro-
portion of cases with pCR but did find that sequencing of
taxanes before anthracyclines led to an overall increase in
pCR [15]. Details of eligibility and ascertainment of clinical
characteristics are provided in the main trial report [15].
The trial was approved by the multicentre research ethics
committee and subsequently by the local research ethics
committees at all participating centres (full names and
details are provided in Additional file 1). All patients
provided written informed consent and the trial was
registered (ClinicalTrials.gov NCT00070278).
Image acquisition, processing and pathology review
Haematoxylin and eosin (H&E)-stained histological
slides from formalin-fixed paraffin embedded (FFPE)
pre-treatment core biopsies and tumours resected at
surgery were requested from all centres for central review
and digitization. Image analysis was conducted by AD at
the Institute of Astronomy in Cambridge, as part of a col-
laboration with Oncology [17]. Our image-processing
pipeline is summarized in Fig. 1. Our approach is entirely
automated and consists of identifying tissue for analysis,
segmenting cell nuclei and finally using machine-learning
to classify nuclei as cancer, stromal or lymphocyte based
on a training set. Adipocytes were included in the stromal
category because based on nuclear features alone, it was
not possible to reliably identify them. Further details are
provided in Additional file 1.
Statistical analyses
All image analyses were conducted prior to receipt of
clinical data from the trial statistician. Associations between
continuous automated image metrics and categorical clin-
ical variables were tested using Wilcoxon’s rank-sum test or
the Kruskal-Wallis test. Pearson’s correlation coefficient
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was used to investigate the relationship between continuous
variables. Logistic regression was used to test for associa-
tions with pCR providing an odds ratio (OR), 95 % confi-
dence interval (CI) and p value. Candidate image-based
predictors were initially tested against pCR in univariate
analysis, with absolute cell counts as log-transformed vari-
ables. Next, a multivariate model was fitted iteratively in a
backward stepwise manner to retain metrics significantly
associated with pCR after adjustment for others remaining
in the model. These metrics were finally included in a
multivariate analysis further adjusted for patient age,
radiological tumour size at diagnosis, lymph node status,
histological grade, ER status and HER2 status. All image
metrics were modelled as continuous variables. Whether
an image metric predicted pCR differently between taxane
sequencing groups (first vs second) was investigated by
inclusion of an interaction term in a logistic regression
model and the fit of this model compared to a model lack-
ing the term using a likelihood ratio test. Statistical ana-
lyses were conducted in Intercooled Stata version 11.2
(Stata Corp, College Station, TX, USA). This study was
conducted in compliance with the Reporting recommen-
dations for tumor marker prognostic studies (REMARK)
criteria [18] as detailed in Additional file 1.
Results
A digital pathology resource and image-processing pipeline
for quantitative cell-level metrics
We used material from 765 patients enrolled in the
Neo-tAnGo randomized controlled trial. Additional file 2
depicts the flow of patients through each analytical stage
in this study. A total of 2,436 slides were received and
digitized, of which 1,992 contained tumour or tumour
bed with the remainder containing adjacent normal
Full-face H&E
scanned images,
consisting of four 
levels (L0,…,L3).
(E)
(D) Output catalogue 
for downstream
morphometric 
estimates e.g.
lymphocyte density 
(shown).
Automated identification of regions of interest and creating 
image blocks.
Segmentation, object detection, SVM-assisted object classification 
(cancer cells, stromal cells and lymphocytes).
Low 
resolution
High 
resolution
L3
L2
L1
L0
(B)
(C)
(A)
Severe
Moderate
Mild
None
P
at
ho
lo
gy
 r
ev
ie
w
ly
m
ph
oc
yt
ic
 in
fil
tr
at
io
n
4 6 8 10 12
Lymphocyte count
0 20 40 60 80
Lymphocyte fraction (%)
-5 -4.5 -4 -3.5 -3
Median lymphocyte density
Fig. 1 Overview of the image processing method. a Full-face H&E scanned images consist of four levels (L0–L3) across a gradation of resolutions.
The levels L3 (lowest resolution) and L0 (highest resolution) are used to process each image. b Automated identification of regions of interest
was performed by dividing image layer L3 into several small blocks (grid) and by analysing the pixel intensity distribution of each block. c Each
image block found to contain tissue was mapped onto layer L0 and image segmentation and object detection (green ellipses) was conducted to
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breast tissue. All images used for analyses are available
to download together with open-source image analysis
code at http://www.ast.cam.ac.uk/~adariush/files/images/
and http://www.ast.cam.ac.uk/~adariush/files/codes/.
On average, each patient’s tumour or residual tumour
bed was represented in 1.2 pre-treatment slides (range
1–23) and 1.8 slides from the post-treatment surgical
specimen (range 1–35). Figure 1 summarizes our novel
image processing pipeline: scanned slide images were ex-
tracted as four layers differing in their size and resolution,
and using the lowest resolution image, areas that con-
tained tissue were automatically identified and white space
was excluded from further analysis. Next, using the high-
est resolution layer, single cell nuclei were detected, and
using a support-vector-machine (SVM) approach trained
using around 1,000 objects per class, cells were sub-
classified into readily distinguishable categories (cancer,
stromal or lymphocyte). Metrics relating to these three cell
types and describing absolute cell number (count), relative
cell type proportion (fraction) and density (minimum, me-
dian and maximum) based on the 50 nearest like-class
neighbors, were computed. That is, every detected cell
was assigned a density estimate based on the distance
between it and the 50 nearest cells of the same type.
Pathologist assessment of lymphocytic infiltration in
pre-treatment biopsies with paired automated data, to
which the pathologist was blinded, was available for
comparison in 377 samples. All automated metrics of
lymphocytic infiltration were significantly associated with
pathologist scores (p <0.0001 for all three comparisons;
Fig. 1), attesting to the validity of the automated image
analysis approach.
Image metrics were calculated for a total of 765 patients
of which 623 provided data on pre-treatment biopsies and
699 provided data on post-treatment surgical samples,
with paired (pre- and post-treatment) data available in 557
patients. Patient and tumor characteristics are detailed in
Table 1. Fifteen machine-learning-derived image metrics
were used for downstream correlative analysis with clinical
and pathological features. Additional files 3 and 4 depict
histograms of the distributions of image metrics for
pre-treatment biopsies and post-treatment surgical
samples. The correlation matrix of image metrics from
data generated using pre-treatment biopsies is depicted
in Additional file 5 and from surgical samples in Additional
file 6. In pre-treatment biopsies, the strongest positive
correlation was between the absolute number of lym-
phocytes and the number of cancer cells (rho = 0.84)
and, conversely, the strongest negative correlation was
between the relative fraction of cancer cells and the
fraction of lymphocytes (rho = –0.59). These contrast-
ing correlations highlight the extent to which absolute
cell counts simply reflect sample cellularity, warranting
cautious interpretation.
Image metrics reflect molecular subtype of the primary
tumor
Figure 2 depicts the distribution of image metrics by the
molecular subtype of the tumour based on ER and HER2
status. The distribution of cancer cell fraction significantly
Table 1 Patient and tumour characteristics
Number Percent
Tumour size
≤50 mm 613 80.1
>50 mm 152 19.9
Total 765 100
Node status
Negative 388 50.7
Positive 377 49.3
Total 765 100
Grade
1 22 2.9
2 245 32
3 328 42.9
Missing 170 22.2
Total 765 100
Taxane sequence
Taxane first 387 50.6
Taxane second 378 49.4
Total 765 100
pCR
No pCR 633 82.7
pCR 122 15.9
Missing 10 1.3
Total 765 100
ER, HER2 status
ER–, HER2– 152 19.9
ER–, HER2+ 64 8.4
ER+, HER2– 342 44.7
ER+, HER2+ 116 15.2
Missing 91 11.9
Total 765 100
Diagnostic biopsies
Missing 142 18.6
Analysed 623 81.4
Total 765 100
Surgical samples
Missing 66 8.6
Analysed 699 91.4
Total 765 100
pCR pathological complete response, ER oestrogen receptor, HER2 human
epidermal growth factor receptor 2
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differed between groups (p = 0.04), with the highest
median cancer cell fraction observed in ER-negative,
HER2-negative tumours. Similarly, the distribution of
stromal cell fraction was significantly different between
groups (p = 0.00001), with the highest median level ob-
served in ER-positive, HER2-negative tumours. The dis-
tribution of lymphocyte fraction was also significantly
different between groups (p = 0.002) with the highest
median level observed in ER-negative, HER2-positive
tumours. Median lymphocyte density was not corre-
lated with patient age at diagnosis (Pearson’s correl-
ation coefficient –0.01), suggesting that the association
with tumour molecular subtype was not age-related.
However, these relationships did not hold following
chemotherapy in post-treatment surgical samples for
which none of the metrics were significantly different
across molecular subtypes (Additional file 7), likely due
to the diminishing influence of tumour cells on the
composition of samples, owing both to widespread cell
death and to other effects of chemotherapy on the tissue
environment.
Chemotherapy response is most strongly associated with
median lymphocyte density
Univariate analysis of the 15 image metrics was con-
ducted using pretreatment biopsies in 614 patients, of
whom 98 (16 %) had tumors that underwent pCR. Six
of the fifteen metrics were significantly (at a nominal
p value <0.05) associated with pCR (Fig. 3 and Additional
file 8). Of these six, four were related to lymphocytes, one
to cancer cells and one to stromal cells. The association
between median lymphocyte density and pCR was by far
the strongest (OR 4.46, 95 % CI 2.34-8.50, p <0.0001) with
the next most significant being maximum lymphocyte
density (OR 3.48, 95 % CI 1.54, 7.86, p = 0.003). To deter-
mine whether sample cellularity influenced the relation-
ship between median lymphocyte density and pCR, a
model adjusted for the total number of cells in a sample
was fit. This showed that sample cellularity had little effect
on this association, which remained significant in the
model (OR 4.56, 95 % CI 2.27, 9.15, p <0.0001). A multi-
variate model comprising these 15 predictors was modi-
fied in a backward stepwise manner resulting in a final
model of 5 significant predictors, including median
lymphocyte density (Additional file 8). However, on further
adjustment of this model for clinical variables only median
lymphocyte density was significantly associated with pCR
(Additional file 9). When included in a multivariate model
with only clinical predictors, median lymphocyte density
remained significantly associated with pCR (OR 2.42, 95 %
CI 1.08, 5.40, p = 0.03; Table 2). However, approximately
one third of observations were lost between univariate
(n = 614) and multivariate analyses (n = 406). For
deciles of median lymphocyte density, differences in
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Fig. 2 Distribution of pre-treatment sample image metrics by tumour molecular subtype. Horizontal grey lines represent median values. Results of
the Kruskal-Wallis test are depicted within graphs; red text denotes p values <0.05. ER oestrogen receptor, HER2 human epidermal growth factor
receptor 2
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the proportion of cases that underwent pCR varied
between 4.9 % (3/61) for the first decile up to 35.5 %
(22/62) for the last.
Figure 4 depicts the distribution of pCR, receptor
status and cellular composition in all samples ranked
according to the median lymphocyte density for each
sample. In addition to depicting the sample-level rela-
tionship between these variables, the relationship be-
tween median lymphocyte density, pCR and molecular
subtype is also depicted in Fig. 4. To address whether
the association between median lymphocyte density and
pCR significantly differed by ER status, we compared the
fit of two logistic regression models: one with an inter-
action term between median lymphocyte density and
ER status, and one without. The likelihood ratio test
comparing these models was not significant (p = 0.72),
however, it should be noted that for comparison of effect
between subgroups these analyses are relatively
underpowered, precluding reliable conclusions. In
addition, Fig. 4 highlights that although higher median
lymphocyte density is generally associated with a larger
lymphocyte fraction (rho = 0.69), it is not simply a re-
flection of higher numbers of infiltrating lymphocytes.
There are both instances where the relative fraction of
lymphocytes is high but where the density of lympho-
cytes is low compared to other samples, and conversely
in some instances the fraction of lymphocytes is
relatively low but their median density is high (Fig. 4).
Additional file 10 depicts this relationship as a scatter
plot, further highlighting the existence of outlier cases.
This suggests that a measure of lymphocytic density
may reflect a functional aspect of the immune response
not entirely encompassed by lymphocyte fraction.
Additional file 11 depicts example images together with
contour representations of lymphocyte density and auto-
mated metrics for each image. Median lymphocyte
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Fig. 3 Association between image metrics and pathological complete response (pCR). Manhattan plot illustrates p values (–log10) from univariate
logistic regression analyses testing the association between 15 image metrics and pCR
Table 2 Univariate and multivariate logistic regression models of clinical factors and median lymphocyte density
Univariate Multivariate
Variable Categories Odds ratio 95 % CI P value Observations Odds ratio 95 % CI P value Observations
Age Continuous 0.99 0.97, 1.02 0.6 755 0.99 0.96-1.02 0.44 406
Tumour size ≤50 mm, >50 mm 0.89 0.54, 1.48 0.66 755 0.68 0.27-1.75 0.43 406
Node status Negative, positive 0.8 0.54, 1.18 0.25 755 0.56 0.31-1.00 0.05 406
Grade 1, 2, 3 3.98 2.38, 6.67 <0.00001 588 3.62 1.74-7.52 0.0006 406
ER status Negative, positive 0.26 0.17, 0.38 <0.00001 755 0.3 0.17-0.53 0.00004 406
HER2 status Negative, positive 1.6 1.03, 2.50 0.04 665 1.81 0.97-3.37 0.06 406
Median lymphocyte density Continuous 4.46 2.34, 8.50 <0.00001 614 2.42 1.08-5.40 0.03 406
ER oestrogen receptor; HER2 human epidermal growth factor receptor 2
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density was positively associated with both axillary
lymph node status (p = 0.002) and histological grade (p
<0.00001) but not with tumor size (p = 0.47) as depicted
in Additional file 12.
Increased post-treatment lymphocyte density is associated
with relative chemoresistance
We further investigated whether the change in median
lymphocyte density between pre- and post-treatment
samples was reflected in the probability of pCR and the
extent to which the degree of change varied between
patients. Change in median lymphocyte density across
all 557 samples for which paired data was available is
depicted as a waterfall plot in Fig. 5. In the majority of
cases (75.6 %, 421/557 cases) lymphocyte density decreased
in the surgical specimen. In addition, on assessment of the
association between change in lymphocyte density and pCR
in the 553 cases with sufficient data, there was strong asso-
ciation between reduction in lymphocyte density in the sur-
gical sample and higher likelihood of pCR (OR 0.28, 95 %
CI 0.17, 0.47, p <0.0001) with 17 % (71/418) of cases with a
decrease in density undergoing pCR, in comparison to just
6.7 % (9/135) of those where there was an increase. Change
in lymphocyte density was negatively correlated with
median lymphocyte density at diagnosis (Correlation
coefficient –0.6, p <0.0001). In a model adjusted for median
lymphocyte density at diagnosis, change in lymphocyte
density remained significantly associated with pCR (OR
0.38, 95 % CI 0.21, 0.71, p = 0.002).
The main finding of the Neo-tAnGo trial was that ad-
ministration of a taxane prior to other chemotherapy
agents led to a significant increase in pCR [15]. There-
fore, we next evaluated whether the association between
increased post-treatment lymphocyte density and reduced
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Fig. 4 Relationship between median lymphocyte density, cellular composition, pathological complete response (pCR) and receptor status. Bar
plots illustrating the relationship between pathological complete response, oestrogen receptor (ER) status, human epidermal growth factor
receptor 2 (HER2) status, cellular composition and median lymphocyte density. Plots are sorted by increasing level of median lymphocyte density.
For illustration, median lymphocyte density has been rescaled to positive values
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Fig. 5 Change in lymphocyte density and association with pathological complete response (pCR). Plot depicts the change in median lymphocyte
density between paired pre-treatment and post-treatment surgical samples. The primary sort key is taxane sequence and the secondary sort key
is change in lymphocyte density. Annotated rug depicts oestrogen receptor (ER), human epidermal growth factor receptor 2 (HER2) status and
taxane sequence for samples corresponding to those depicted in the plot above
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likelihood of pCR was equally distributed according to
whether a taxane was received first or second (Fig. 5). The
association between increased post-treatment lymphocyte
density and reduced likelihood of pCR was significantly
stronger where a taxane was received second compared to
where it was received first (likelihood-ratio test for inter-
action, p = 0.02). The OR in the taxane second group was
0.12 (95 % CI 0.05, 0.31, p <0.0001) compared to 0.45
(95 % CI 0.24, 0.84, p = 0.01) in the taxane first group. It
should be noted that the proportion of cases with in-
creased post-treatment lymphocyte density was equally
distributed across taxane groups (24 % and 25 %).
Discussion
We used computational pathology to generate image
metrics of both pre- and post-treatment biopsies in a
randomized controlled trial of neoadjuvant chemother-
apy in breast cancer in order to investigate associations
with chemosensitivity. Median lymphocyte density in pre-
treatment biopsies emerged as the best predictor of re-
sponse to chemotherapy, improving prediction based on
known clinical factors. In addition, change in lymphocyte
density between pre and post-treatment samples revealed
that an increase in lymphocyte density was, paradoxically,
associated with relative chemoresistance.
Computational pathology was used here to generate
objective quantitative estimates of the cellular compos-
ition of tissue samples and, importantly, of the spatial
heterogeneity of different cell types across a tissue sec-
tion. Median density of lymphocytes, a spatial estimate,
outperformed simple cellular quantification. Similarly,
we have previously reported that the spatial distribution
of stromal cells is prognostic in breast cancer and that
this feature is not easily measurable by genomic assays
[13]. Previous work in the context of breast and prostate
cancer, has demonstrated the capacity of a computational
approach to interrogate spatial, relational and geometric
features of tissues for outcome prediction [14, 19, 20].
Many of these parameters could not be practically esti-
mated by other means, and in this respect machine
learning can provide deeper insight into tissue morph-
ology than is possible by manual evaluation.
We performed a data-driven selection of tissue fea-
tures associated with pCR. Median lymphocyte density
emerged as the best predictor of chemosensitivity. In a
previous study we have reported an association between
automated estimates of lymphocytic infiltration and breast
cancer survival in ER-negative disease [13, 21]. Similarly,
studies of patients who received neo-adjuvant chemother-
apy based on genomic assays and histopathology have also
reported an association between the immune response
and pCR [22]. Ignatiadis et al. conducted a meta-analysis
of gene-expression data from pre-surgical specimens in
996 patients and investigated associations between 17
previously reported gene modules and pCR [22]. They
found that the gene modules most reliably associated
with pCR across cancer subtypes were those relating to
the immune response. Tumour infiltrating lymphocytes
estimated by a pathologist from H&E sections have also
been found to be associated with outcome and response
to chemotherapy [8, 23], including some in the neo-
adjuvant setting [6, 10], largely in accord with the findings
of this study.
To our knowledge, this is the first report showing that
an increase in lymphocyte density following the perturb-
ation of chemotherapy is associated with a lower likeli-
hood of pCR. Previous studies have also shown that the
composition of the post-treatment immune repertoire is
associated with survival [24, 25]. In addition, we found
that the sequence in which chemotherapy agents were
administered affected the strength of this association.
Where patients received a taxane second, increased
lymphocyte density was more strongly associated with
relative resistance to chemotherapy than in patients who
received a taxane first.
A limitation of this study is that we were not able to
digitize and analyse samples from all patients enrolled in
the Neo-tAnGo trial and that associated clinical data
were not complete, leading to a loss of around one third
of observations in multivariate analyses. This is inevit-
able in the context of large multicentre trials. A second
limitation is that by using H&E sections we have not
accounted for the immune phenotype or functional state
of infiltrating lymphocytes.
The functional basis of the interaction we observed
between the immune response and chemotherapy is
uncertain. It should, however, be noted that all patients
received an anthracycline (epirubicin) as part of their
treatment. Anthracyclines have been extensively investi-
gated in pre-clinical studies as a chemotherapeutic agent
with a tumoricidal effect that can in part be attributed to
stimulation of the immune response [26]. For example, a
recent study reported that upon exposure to an anthracy-
cline tumour cells produce type I interferons evoking an
immunological cascade reminiscent of that seen in cells
infected by a virus and that this effect may be partly ex-
plained by the release of self-RNAs by dying cells [27].
That greater clinical benefit of anthracyclines is signifi-
cantly associated with the presence of a pre-existing im-
mune response (tumour-infiltrating lymphocytes) has also
been shown in several clinical studies [8, 23, 28]. However,
our results suggest that the effect of chemotherapy may be
more complex than simply boosting pre-existing immune
attack. First, we find that where the density of lymphocytes
is increased following treatment, fewer tumours undergo
pCR. That is, in this subset of around one quarter of pa-
tients, tumour cells apparently continue to resist the ef-
fects of immune attack in spite of its increased intensity.
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Second, we find that this effect is significantly greater
where a taxane (paclitaxel) was administered after, as
opposed to before, other agents. In the Neo-tAnGo
trial, giving paclitaxel before the other agents signifi-
cantly increased the proportion of cases with pCR [15].
While the association between increased post-treatment
lymphocyte density and treatment resistance holds
whether paclitaxel is given first or second, the effect is
significantly larger in cases where it is given second.
Collectively, these findings raise the possibility that not
only is a chemotherapy-stimulated immune response
not universally effective, but that the efficacy of this re-
sponse can be influenced by the sequence in which
tumour cells are exposed to different chemotherapeutic
agents, most notably taxanes and anthracyclines.
The existence of a substantial subgroup of relatively
resistant tumours in which lymphocyte density is in-
creased following chemotherapy further suggests a clinical
opportunity. The variability in the immune response be-
tween primary breast tumours is well-known and recent
genomic analyses suggest that some of this difference may
be explained by the mutational burden of the primary
tumour [29]. Analyses of clinical trials of immune check-
point inhibitors report that responses are best where there
is a significant pre-existing immune response to the
primary tumour [30, 31]. Given that a large subset of
breast tumours evoke only a mild immune response if
any [23, 32], methods for increasing immune attack
against immunologically quiescent tumours are needed.
Therefore the subgroup we have identified may benefit
from receiving chemotherapy first, to increase the im-
mune response, followed by immune checkpoint inhibi-
tors to amplify its effect.
Digitization of pathology slides from clinical trials
affords the important advantages of providing an enduring
archive of tumour pathology and the opportunity for
systematic image analysis. We anticipate analyses such
as ours becoming more common as digital pathology is
implemented more widely in clinical trials. We provide
a valuable resource of digital pathology images to the
research community, together with all our image-analysis
codes. In addition, linked multiplatform genomic annota-
tion (gene expression, copy number, targeted sequencing)
will be made available for a subset of cases, following pri-
mary reporting of the data. While invaluable resources
such as the Human Protein Atlas already provide access
to an enormous array of tissue images [33], some already
utilized in translational studies [34, 35], widely available
digital images of tumour tissue from large high-quality
clinical studies with molecular annotation such as ours are
currently exceedingly rare. However, general access to
such resources will be necessary to fulfil the potential of
computational pathology as a novel modality that spans
the research and clinical arenas.
Conclusions
This data-driven analysis of computational pathology
metrics reveals that median lymphocyte density is an
independent predictor of response to neoadjuvant chemo-
therapy in breast cancer. Paradoxically, we find that an
increase in the density of lymphocytes following
chemotherapy is associated with relative resistance to
chemotherapy. Computational pathology is a novel and
quantitative method for interrogation of tumour tissues,
which can improve prediction of clinical endpoints.
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